Trial Profile
An Open Multi-centre Study in Patients With Von Willebrand Disease to Investigate the Pharmacokinetics, Efficacy and Safety of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Pharmacokinetics
- Sponsors Bio Products Laboratory
- 21 Apr 2014 Planned End Date changed from 1 Sep 2008 to NULL.
- 21 Apr 2014 New trial record